Date: September 28, 2026

Dividend Declaration or Non-Declaration

Jubilant Pharmova Limited has withheld the final dividend for the financial year 2025-26 for shareholders holding securities in physical form who have not submitted complete KYC documents. The dividend will be paid only through electronic mode after requisite KYC and bank account details are registered and validated with the company/Registrar & Share Transfer Agent (RTA).

Reason for withholding: Non-submission or incomplete KYC particulars including PAN, postal address, email address, mobile number, bank account details, and specimen signature.

Record Date: July 24, 2026

Dividend Details (Specimen Table):

The announcement includes a specimen table for affected shareholders showing:

  • Number of equity shares held on record date
  • Dividend per share (INR)
  • Gross dividend amount (INR)
  • Tax deducted at source (INR)
  • Rate at which tax is deducted (%)
  • Payment date
  • Status of Payment
  • Reason for withholding

Required Actions for Shareholders:

Affected shareholders must submit the following documents to the RTA, Alankit Assignments Limited:

  • Form ISR-1 for KYC update with self-attested supporting documents
  • Form ISR-2 for banker attestation of signature with original cancelled cheque or self-attested copy of bank passbook/statement
  • Form SH-13 for updation of Nomination; or Form ISR-3 for "Opt-out of the Nomination"

RTA Contact Information:

Alankit Assignments Limited

205-208, AnarKali Complex, Jhandewalan Extension

New Delhi - 110 055

Regulatory Reference:

SEBI Master Circular No. HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026, read with Regulation 12 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Other Operational / Legal / Strategic Disclosures

The company has complied with SEBI regulations by intimating the exchanges about the dividend withholding and providing specimen letters to affected shareholders. The information is also available on the company's website at www.jubilantpharmova.com.

No material disclosures under the following sections:

  • KMP / Board / Auditor Changes
  • Board Meeting Outcomes
  • Financial Results (Standalone & Consolidated)
  • Auditor's Report
  • Disinvestment / Strategic Actions
  • Media Release / Investor Communication